23897969	207	Iyer G	Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.	Journal of clinical oncology 	2013	58
25500544	238	Yoshihara K	The landscape and therapeutic relevance of cancer-associated transcript fusions.	Oncogene	2015	56
25498841	1019	Carneiro BA	Emerging therapeutic targets in bladder cancer.	Cancer treatment reviews	2015	16
23887298	1029	Ross JS	Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.	Modern pathology 	2014	36
25092538	1029	Kim PH	Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.	European urology	2015	19
26420858	1493	Mak MP	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.	Clinical cancer research 	2016	24
15753357	1956	Shigematsu H	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.	Cancer research	2005	142
22452803	1956	Fokas E	NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.	Radiation oncology	2012	30
24656976	1956	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	40
23852170	2064	Roberts SA	An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.	Nature genetics	2013	205
24960601	2064	Choi W	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.	Nature reviews. Urology	2014	30
25636205	2064	Groenendijk FH	ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.	European urology	2016	15
21119661	2260	Lamont FR	Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.	British journal of cancer	2011	42
17668422	2261	Tomlinson DC	FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.	The Journal of pathology	2007	63
19381019	2261	Qing J	Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.	The Journal of clinical investigation	2009	62
19843843	2261	Catto JW	Distinct microRNA alterations characterize high- and low-grade bladder cancer.	Cancer research	2009	89
21072204	2261	Kompier LC	FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.	PloS one	2010	63
22045636	2261	Foldynova-Trantirkova S	Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.	Human mutation	2012	41
25194568	2261	Rampias T	A new tumor suppressor role for the Notch pathway in bladder cancer.	Nature medicine	2014	21
26901314	2261	Ward DG	Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer.	PloS one	2016	11
22331944	2956	Win AK	Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.	Journal of clinical oncology 	2012	68
23091106	2956	Engel C	Risks of less common cancers in proven mutation carriers with lynch syndrome.	Journal of clinical oncology 	2012	32
15572290	3251	DeMarini DM	Genotoxicity of tobacco smoke and tobacco smoke condensate: a review.	Mutation research	2004	95
6298635	3265	Capon DJ	Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue.	Nature	1983	213
2453289	3845	Almoguera C	Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.	Cell	1988	407
11459867	3845	Adjei AA	Blocking oncogenic Ras signaling for cancer therapy.	Journal of the National Cancer Institute	2001	157
16449975	6422	Veeck J	Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis.	Oncogene	2006	76
23348506	7015	Huang FW	Highly recurrent TERT promoter mutations in human melanoma.	Science	2013	346
24018021	7015	Allory Y	Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.	European urology	2014	37
24101484	7015	Rachakonda PS	TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.	Proceedings of the National Academy of Sciences of the United States of America	2013	55
24121487	7015	Kinde I	TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.	Cancer research	2013	41
25722414	7015	Borah S	Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.	Science	2015	59
10720328	7157	Fliss MS	Facile detection of mitochondrial DNA mutations in tumors and bodily fluids.	Science	2000	182
24469795	7157	Morrison CD	Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
25538195	7157	Vieira VC	Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B.	mBio	2014	33
22923433	7248	Iyer G	Genome sequencing identifies a basis for everolimus sensitivity.	Science	2012	158
23852168	9582	Burns MB	Evidence for APOBEC3B mutagenesis in multiple human cancers.	Nature genetics	2013	159
23175443	10460	Williams SV	Oncogenic FGFR3 gene fusions in bladder cancer.	Human molecular genetics	2013	81
23696246	10460	Katoh M	FGF receptors: cancer biology and therapeutics.	Medicinal research reviews	2014	68
15867337	11186	Agathanggelou A	Role of the Ras-association domain family 1 tumor suppressor gene in human cancers.	Cancer research	2005	108
15829956	11200	Bartkova J	DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.	Nature	2005	819
